New cancer biology work mapped why immunotherapy can fail and how tumors rewire cell death and metabolism. A study described chromosomal chaos in tumors as a potential driver of immune blindness, suggesting that large-scale genome disruption may reshape the local immune landscape. In gastrointestinal oncology, additional preclinical work pointed to a hidden protein signal network that drives why checkpoint inhibitors do not translate into durable control in gut cancers. The same theme carried into colorectal cancer mechanistic research showing lactylation-linked pathways helping chemotherapy escape by enabling hidden survivors. On the therapy-target axis, multiple studies emphasized that resistance isn’t only about antigen loss or pathway switching—it can be orchestrated by epigenetic and metabolic remodeling, reinforcing the need for multi-layer biomarker discovery in drug development.